~~<i id='B35D2C5093'><strike id='B35D2C5093'><tt id='B35D2C5093'><pre id='B35D2C5093'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：entertainment 2025-09-06 09:55:35 Page View：9626

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ProMED, early warning system on disease outbreaks, in peril
Next article： Virginia high school admissions case could be legal follow

focus

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

My superpower is killing ticks

EssayauthorRichardS.Ostfeldhasdevelopedanimmunitythatkillstickswhentheytrytobitehim.CDCSometimespeop

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

OTC birth control: A brief history of over the counter pill design

Illustration:AlexHogan/STAT;Photo:CourtesyPerrigoIt’snoteverydaythatamarketingteamistaskedwithdesign